TimesSquare Capital Management LLC Sells 29,719 Shares of CeriBell, Inc. $CBLL

TimesSquare Capital Management LLC lessened its holdings in CeriBell, Inc. (NASDAQ:CBLL) by 3.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 787,926 shares of the company’s stock after selling 29,719 shares during the quarter. TimesSquare Capital Management LLC owned 2.12% of CeriBell worth $17,279,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Emerald Mutual Fund Advisers Trust raised its stake in CeriBell by 58.2% in the third quarter. Emerald Mutual Fund Advisers Trust now owns 155,360 shares of the company’s stock valued at $1,785,000 after purchasing an additional 57,175 shares in the last quarter. CenterBook Partners LP raised its stake in CeriBell by 448.0% in the third quarter. CenterBook Partners LP now owns 476,554 shares of the company’s stock valued at $5,476,000 after purchasing an additional 389,584 shares in the last quarter. JPMorgan Chase & Co. raised its stake in CeriBell by 8.2% in the third quarter. JPMorgan Chase & Co. now owns 411,180 shares of the company’s stock valued at $4,724,000 after purchasing an additional 31,177 shares in the last quarter. GSA Capital Partners LLP acquired a new position in CeriBell in the third quarter valued at about $158,000. Finally, Invesco Ltd. acquired a new position in CeriBell in the second quarter valued at about $197,000.

Insiders Place Their Bets

In other CeriBell news, CEO Xingjuan Chao sold 39,000 shares of the business’s stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $17.45, for a total transaction of $680,550.00. Following the completion of the transaction, the chief executive officer owned 711,164 shares of the company’s stock, valued at approximately $12,409,811.80. The trade was a 5.20% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Josef Parvizi sold 16,714 shares of the business’s stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $20.27, for a total value of $338,792.78. Following the transaction, the director directly owned 722,652 shares of the company’s stock, valued at approximately $14,648,156.04. The trade was a 2.26% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 175,119 shares of company stock worth $3,310,772 in the last ninety days. Insiders own 20.10% of the company’s stock.

CeriBell Stock Up 2.3%

Shares of NASDAQ CBLL opened at $16.96 on Wednesday. The company has a current ratio of 10.44, a quick ratio of 10.01 and a debt-to-equity ratio of 0.14. The company has a market cap of $643.51 million, a price-to-earnings ratio of -10.40 and a beta of 0.99. CeriBell, Inc. has a 12 month low of $10.85 and a 12 month high of $24.33. The stock has a 50-day moving average price of $19.07 and a two-hundred day moving average price of $18.98.

CeriBell (NASDAQ:CBLL) last issued its earnings results on Monday, May 11th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.13). The business had revenue of $26.49 million for the quarter, compared to analyst estimates of $26.09 million. CeriBell had a negative return on equity of 38.19% and a negative net margin of 63.51%. As a group, analysts forecast that CeriBell, Inc. will post -1.69 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on CBLL shares. Canaccord Genuity Group dropped their price target on CeriBell from $28.00 to $25.00 and set a “buy” rating for the company in a research note on Tuesday, May 12th. Weiss Ratings downgraded CeriBell from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, May 12th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $30.00 price target on shares of CeriBell in a research note on Wednesday, January 28th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $22.20.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.